The Investor Relations website contains information about EyePoint Pharmaceuticals's business for stockholders, potential investors, and financial analysts.
EyePoint Pharmaceuticals,Inc .(纳斯达克:EYPT)今天宣布,第一位患者已在LUCIA试验中给药,这是该公司对DURAVYU(原EYP-1901)进行的第二个全球3期临床试验,用于治疗湿性老年黄斑变性(湿性AMD)。DURAVYU是一种研究中的持续给药疗法,提供受专利保护的vorolanib,这是一种选择性酪氨酸激酶抑制剂,采用专有的可生物侵...
The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.Headline NewsWed, 16 Apr 2025EyePoint Pharmaceuticals Reports Inducement ...
EyePoint Pharmaceuticals,Inc .(纳斯达克:EYPT)今天宣布了EYP-1901的2期DAVIO 2临床试验的新亚组分析结果,该试验是一项针对湿性年龄相关性黄斑变性(湿性AMD)的研究性持续给药维持治疗,结合了选择性酪氨酸激酶抑制剂vorolanib和生物可蚀性Durasert E .这些数据在2024年2月3日举行的2024年血管生成、渗出和变性会议...
EyePoint Pharmaceuticals,Inc .(纳斯达克:EYPT)今天宣布,第一位患者已在EYP-1901用于糖尿病性黄斑水肿(DME)的2期VERONA临床试验中给药。EYP-1901是一种研究中的缓释治疗药物,含有vorolanib,这是一种选择性酪氨酸激酶抑制剂 “VERONA期试验中的第一位患者的用药代表了我们在推进改善严重视网膜疾病患者生活的使命方面...
DURAVYU™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU™ is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain. ...
马萨诸塞州沃特敦 - EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) 今日公布了其用于治疗糖尿病黄斑水肿(DME)的DURAVYU药物的VERONA二期临床试验中期结果。数据显示患者的视力和视网膜厚度均有显著改善。 这项评估DURAVYU(一种持续给药疗法)有效性的试验显示,最佳矫正视力(BCVA)从基线早期开始持续提高8.9个字母,超...
2025年2月5日,EyePoint Pharmaceuticals宣布其进行中的VERONA临床2期试验的六个月积极结果。根据我搜索到的资料,该试验主要评估了DURAVYU(一种玻璃体植入疗法,即伏罗尼珠单抗)在治疗糖尿病性黄斑水肿(DME)患者中的疗效和安全性。 试验背景与设计 VERONA是一项随机、对照、单盲、多中心的2期临床试验,旨在评估DURAVYU...
WATERTOWN, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that company ma...
EyePoint Pharmaceuticals决定启动公开发行之际,公司正经历重大财务动态。根据InvestingPro数据,截至2024年第二季度的过去十二个月,EyePoint的收入增长强劲,增幅达34.98%。这一增长轨迹与公司为其临床开发项目(特别是DURAVYU™)筹集资金的需求相一致。 第三方广告。非Investing.com产品或者推荐。点击此处查看声明或者移除广...